北京若生智能科技有限公司
Drug Database
AC

acetylsalicylic acid + clopidogrel (Copregrel / Coprigrel)

✓ Approved

Chong Kun Dang Pharmaceutical · PTGS1 · 小分子

什么是 acetylsalicylic acid + clopidogrel？

acetylsalicylic acid + clopidogrel 是一种小分子，由Chong Kun Dang Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Copregrel, Coprigrel
公司Chong Kun Dang Pharmaceutical
药物类别小分子
分子靶点PTGS1, PTGS2, P2RY12
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Chong Kun Dang Pharmaceutical

作用机制

分子靶点

acetylsalicylic acid + clopidogrel 作用于 3 个分子靶点：

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
P2RY12purinergic receptor P2Y12 (P2Y(ADP), P2Y(cyc))
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

acetylsalicylic acid + clopidogrel 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedCurrent oncology (Toronto, Ont.)2026-10-26

Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM).

Strelau Matthew M, Gal Gregoire Le GL, McCurdy Arleigh A, Shivakumar Sudeep S et al.

Venous thromboembolism is a serious medical complication with an increased risk in patients with multiple myeloma undergoing combination treatment regimens. Acetylsalicylic acid is routinely used as a method of thromboprophylaxis in multiple myeloma patients treated with lenalidomide, and rivaroxaban has been assessed in small-scale studies in multiple myeloma patients treated with immunomodulatory drugs; yet, no study has compared the two methods. In this pilot, we asked if a full-scale trial would be feasible to assess the benefits of rivaroxaban over acetylsalicylic acid as a thromboprophylactic approach. This pilot recruited patients with multiple myeloma on lenalidomide-based therapy and randomized them to either low-dose acetylsalicylic acid or rivaroxaban, then monitored bleeding and thrombotic events throughout lenalidomide-dexamethasone treatment. A total of 55 patients were recruited across three Canadian centres, with two venous thromboembolic events and two bleeding events, all in the acetylsalicylic acid arm. We conducted a post hoc analysis of active recruitment time as a definition of recruitment feasibility, as we did not achieve our pre-defined feasibility goals. Despite the challenges in enrollment, possibly due to social restrictions during the COVID-19 pandemic, we maintain that a full-scale trial is feasible and offers insight into thromboprophylactic management in this population.

PMID 42930200
阅读全文 →
PubMedCureus2026-10-26

Ticagrelor-Induced Bradyarrhythmias in Acute Coronary Syndrome: A Case Series of Three Patients.

Molleti Ashish A, Sankaran Ramesh R, Vinod Kumar Balakrishnan B, Arul Judah N JN

Ticagrelor is a reversible oral P2Y12 receptor inhibitor recommended in preference to clopidogrel for most patients with acute coronary syndrome. In addition to inhibiting platelets, it raises extracellular adenosine, which is thought to explain its underappreciated capacity to cause bradyarrhythmia. We report three consecutive patients with acute coronary syndrome who developed serious bradyarrhythmias after ticagrelor administration. The first, a 58-year-old woman treated with a drug-eluting stent to the left anterior descending artery, developed high-grade atrioventricular block with asystolic pauses that required a temporary pacing wire, after which ticagrelor was stopped, prasugrel was substituted, and she recovered. The second, a 48-year-old woman with an anterior myocardial infarction, had a cardiac arrest with complete heart block after ticagrelor loading, was resuscitated, paced temporarily, switched to prasugrel, and recovered. The third, a 77-year-old man with an inferoposterior and right ventricular myocardial infarction, had recurrent asystole and ventricular arrhythmia that persisted despite switching to prasugrel and required a permanent pacemaker. None of the patients were receiving an atrioventricular nodal blocking drug, and in every patient the treated coronary lesion was patent on a repeat angiogram, which made ongoing ischemia from stent failure an unlikely sole explanation. A formal Naranjo assessment rated the association as possible in each case. A ticagrelor-induced adverse effect should be considered in any patient who develops unexplained bradycardia or syncope after its administration. Early rhythm monitoring and prompt withdrawal are the key steps, and although the rhythm usually recovers, permanent pacing may be needed when conduction disease is superimposed on ischemic injury to the conduction system.

PMID 42928934
阅读全文 →
PubMedPakistan journal of pharmaceutical sciences2026-10-26

Stability studies and characterization of nanoemulgel containing gallic acid.

Awan Hina H, Khan Hira H, Haq Rizwan Ul RU, Fatima Nighat N et al.

Gallic acid is a natural phenolic compound with excellent antioxidant, antimicrobial and anti-inflammatory activity and good skin penetration. Gallic acid demonstrates both stability and solubility problems in topical formulations. A nanoemulgel combines an emulsion for enhanced solubility with a gel base for improved physical stability. The main objective of this study is to characterize and assess the stability of a gallic acid-containing nanoemulgel. Various gallic acid nanoemulsions (GNE) were prepared using optimized ratios of oil, surfactants, gallic acid and water and evaluated for stability. Finally, stable GNE-19 was characterized for particle size and converted to nanoemulgel (GNEG-19). Nanoemulgel was subjected to short-term and accelerated stability studies and characterized for pH, viscosity, spreadability, occlusion effect, FTIR, in-vitro drug release and in-vitro pharmacological activities. The results showed that formulation GNEG-19 showed optimum thermodynamic stability, having no phase separation and color change. The droplet size of freshly prepared GNE and after 28 days was 175.43nm and 183.23nm, respectively. The pH was slightly acidic but still within the human skin range (3.9-4.5). No interaction was found between the gallic acid and other components of nanoemulgel following FTIR analysis. The viscosity of freshly prepared GNEG-19 was 2127.1 cP and after 90 days, it was 2102.3 cP, which showed its stability. The percent drug release of gallic acid from nanoemulgel after 24 hrs was 93.12%. GNEG-19 also showed effective occlusion properties when compared with gel base and petroleum jelly. In-vitro pharmacological activities showed that GNEG-19 had antioxidant activity of 63.77% and a zone of inhibition (ZOI) of 11.4 mm compared to pure gallic acid (9.5 mm). In conclusion, nanoemulgel containing gallic acid showed good physical and chemical stability and was pharmacologically active.

PMID 42929401
阅读全文 →
PubMedGels (Basel, Switzerland)2026-10-26

Cyclodextrin-Containing Tannic Acid-Lipoic Acid Hydrogels for the Loading and Reduction-Responsive Release of Nile Red.

Zhu Yuzheng Y, Kobayashi Kazuya U KU, Hatano Akihiko A, Suzuki Manabu M et al.

Hydrophobic molecules are generally difficult to incorporate into aqueous hydrogels because of their poor water solubility. In this study, a cyclodextrin (CD)-containing tannic acid-lipoic acid (TA-LA) hydrogel was developed using lipoic acid-modified β-cyclodextrin (LACD). LACD retained the host-guest recognition ability of the cyclodextrin cavity after lipoic acid modification and was successfully incorporated into the TA-LA hydrogel without interfering with gel formation. Using Nile Red (NR) as a model hydrophobic molecule, the LACD-containing hydrogel showed higher NR encapsulation efficiency and greater cyclodextrin retention than the hydrogel containing unmodified β-cyclodextrin. The LACD-containing hydrogel also exhibited reduction-responsive NR release in the presence of dithiothreitol (DTT). These results show that LACD can be incorporated into the TA-LA hydrogel while retaining the host-guest recognition ability of the cyclodextrin cavity and can be used for reduction-responsive release of NR.

PMID 42929903
阅读全文 →
PubMedPakistan journal of pharmaceutical sciences2026-10-26

Chicoric acid regulates IL-1β to improve the inflammatory response in mice undergoing myomectomy under propofol anesthesia.

Zhai Zixuan Z, Zhao Zheng Z, Yu Jianfeng J

Surgical excision of uterine fibroids triggers acute inflammation, impacting postoperative recovery. Propofol anesthesia may modulate this response. Chicoric acid possesses anti-inflammatory properties, but its perioperative utility remains unexplored. To investigate whether preoperative chicoric acid enhances the anti-inflammatory effect of propofol in a mouse model of myomectomy and to explore the involvement of the p38 MAPK/NF-κB/IL-1β axis. A human uterine fibroid xenograft mouse model was established using CB-17 SCID mice. Mice underwent simulated myomectomy under propofol or ketamine anesthesia, with or without preoperative chicoric acid (50 mg/kg, 7 days). Controls included sham and model groups. The p38 MAPK/NF-κB agonist LPS and the IL-1β blocker Rilonacept were used to probe mechanisms. Inflammatory cytokines (MSD), pathway protein expression (Western blot), and uterine histopathology (H&E) were assessed 12h post-surgery. Propofol anesthesia significantly inhibited surgery-induced p38 MAPK/NF-κB activation and reduced levels of inflammatory cytokines compared with the model group. Preoperative cholic acid further suppressed this pathway and enhanced the anti-inflammatory effect beyond that of propofol alone. LPS reversed chicoric acid's effects, confirming the involvement of the pathway. Unexpectedly, Rilonacept did not enhance but rather reversed the anti-inflammatory effect of chicoric acid, suggesting complex, compensatory interactions within a cytokine network. Preoperative chicoric acid augments propofol's anti-inflammatory effect during myomectomy by inhibiting the p38 MAPK/NF-κB pathway. However, the paradoxical effect of IL-1β blockade reveals unforeseen complexity in the perioperative cytokine network, warranting further investigation into the multitarget effects of chicoric acid and potential network-compensation mechanisms.

PMID 42929413
阅读全文 →
PubMedEuropean journal of immunology2026-10-26

Cholic Acid Reprograms RORγt+ Th17 Cells into IL-10-Producing T Cells to Limit Experimental Colitis.

Dalal Rajdeep R, Sadhu Srikanth S, Singla Poonam P, Madan Upasna U et al.

Inflammatory bowel disease (IBD) is a relapsing-remitting inflammatory disorder of the gastrointestinal tract driven by dysregulated T helper (Th)-cell responses, gut microbiota imbalance, and altered bile acid metabolism. While cholic acid (CA), a primary bile acid, is immunotoxic at high concentrations, its immunomodulatory role at physiological levels remains unclear. Here, we evaluate the therapeutic potential of CA in an experimental colitis model. Administration of biologically tolerable CA significantly reduced disease activity, preserved colon length, and alleviated histological inflammation. Mechanistically, CA downregulated RORγt levels and promoted Th cell plasticity toward IL-10-producing phenotypes, resulting in diminished production of IFN-γ and IL-17. Dietary depletion of primary bile acid precursors and IL-10 neutralization confirmed IL-10-dependent immunoregulation as a key mechanism. Additionally, synthetic derivatives of CA, similar to CA, attenuated DSS-induced colitis by selectively expanding IL-10-producing Th cells. Collectively, these findings highlight CA and its synthetic derivatives as immunomodulatory candidates for the therapy of ulcerative colitis.

PMID 42929495
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多acetylsalicylic acid + clopidogrel